FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 356:437-440 February 1, 2007 Number 5 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Two modern-day epidemics, HIV–AIDS and type 2 diabetes mellitus, have inspired impassioned calls for more effective interventions. In the 1980s, the rapid spread of HIV, with its associated severe, acute illness and high mortality, prompted activist groups and others to call for the accelerated approval of medications that showed promise of efficacy. There was no treatment available, and people were dying quickly. More recently, pressure to develop new drugs for type 2 diabetes has been stimulated by the remarkable worldwide increase in the incidence of this disease (54% in the past 7 years in the United States¹) and the . . . [Full Text of this Article]

Source Information

Dr. Nathan is the director of the Diabetes Center at Massachusetts General Hospital and a professor of medicine at Harvard Medical School — both in Boston.

This article has been cited by other articles:

• DeAngelis, C. D., Cooper, D. S., Fontanarosa, P. B. (2008). Diabetes Mellitus--A Call for Papers. JAMA 300: 441-441 [Full Text]  
• Forssmann, U., Stoetzer, C., Stephan, M., Kruschinski, C., Skripuletz, T., Schade, J., Schmiedl, A., Pabst, R., Wagner, L., Hoffmann, T., Kehlen, A., Escher, S. E., Forssmann, W.-G., Elsner, J., von Horsten, S. (2008). Inhibition of CD26/Dipeptidyl Peptidase IV Enhances CCL11/Eotaxin-Mediated Recruitment of Eosinophils In Vivo. J. Immunol. 181: 1120-1127 [Abstract] [Full Text]  
• Yang, W., Ji, Q., Zhu, D., Yang, J., Chen, L., Liu, Z., Yu, D., Yan, L. (2008). Biphasic Insulin Aspart 30 Three Times Daily Is More Effective Than a Twice-Daily Regimen, Without Increasing Hypoglycemia, in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Drugs. Diabetes Care 31: 852-856 [Abstract] [Full Text]  
• Cauley, J. A., Ensrud, K. E. (2008). Considering Competing Risks . . . Not All Black and White. Arch Intern Med 168: 793-795 [Full Text]  
• Inzucchi, S. E., McGuire, D. K. (2008). New Drugs for the Treatment of Diabetes: Part II: Incretin-Based Therapy and Beyond. Circulation 117: 574-584 [Abstract] [Full Text]  
• Grouzmann, E., Buclin, T. (2008). Is Dipeptidylpeptidase IV the Missing Link in Angiotensin-Converting Enzyme Inhibitor Induced Angioedema?. Hypertension 51: 45-47 [Full Text]  
• Misbin, R. I. (2007). Lessons From the Avandia Controversy: A new paradigm for the development of drugs to treat type 2 diabetes. Diabetes Care 30: 3141-3144 [Full Text]  
• Ahima, R. S. (2007). Antagonism of Ghrelin for Glycemic Control in Type 2 Diabetes Mellitus?. Endocrinology 148: 5173-5174 [Full Text]  
• Pogach, L. M. (2007). "Doctor, How Certain Are We That This Diabetes Medication Is Best for Me?". ANN INTERN MED 147: 428-430 [Full Text]  
• Bollyky, J., Greenbaum, C. J. (2007). The Role of Glucagon in Postprandial Hyperglycemia The Jury's Still Out. J. Clin. Endocrinol. Metab. 92: 2879-2881 [Full Text]  
• Amori, R. E., Lau, J., Pittas, A. G. (2007). Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis. JAMA 298: 194-206 [Abstract] [Full Text]  
• Nathan, D. M. (2007). Rosiglitazone and Cardiotoxicity -- Weighing the Evidence. NEJM 357: 64-66 [Full Text]  
• Shuchman, M. (2007). Drug Risks and Free Speech -- Can Congress Ban Consumer Drug Ads?. NEJM 356: 2236-2239 [Full Text]  
• Bloomgarden, Z. T., Inzucchi, S. E., Irony, I., Parks, M. H., Meyer, R. J., Mintz, M. L., Raz, I., Eldor, R., Nathan, D. M. (2007). New Treatments for Diabetes. NEJM 356: 2219-2223 [Full Text]  
• Zarin, D. A., Ide, N. C., Tse, T., Harlan, W. R., West, J. C., Lindberg, D. A. B. (2007). Issues in the Registration of Clinical Trials. JAMA 297: 2112-2120 [Abstract] [Full Text]  
• Malozowski, S. (2007). Exenatide in Combination Therapy: Small Study, Big Market, and Many Unanswered Questions. ANN INTERN MED 146: 527-528 [Full Text]